[{"id":"1b39475a-c778-482c-b273-baa5f64197c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03114319","created_at":"2021-01-18T15:21:08.086Z","updated_at":"2024-07-02T16:34:59.273Z","phase":"Phase 1","brief_title":"Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03114319","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e batoprotafib (TNO155) • nazartinib (EGF816)"],"overall_status":"Recruiting","enrollment":" Enrollment 255","initiation":"Initiation: 05/26/2017","start_date":" 05/26/2017","primary_txt":" Primary completion: 06/11/2025","primary_completion_date":" 06/11/2025","study_txt":" Completion: 06/11/2025","study_completion_date":" 06/11/2025","last_update_posted":"2024-06-04"},{"id":"c2c2adc0-fff1-4c4f-86b0-e88c3d04d52a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06435455","created_at":"2024-05-31T20:35:26.953Z","updated_at":"2024-07-02T16:34:59.697Z","phase":"Phase 1/2","brief_title":"GH21 Combined With D-1553 With Advanced Solid Tumors","source_id_and_acronym":"NCT06435455","lead_sponsor":"Suzhou Genhouse Bio Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib) • HBI-2376"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-05-31"},{"id":"d384c3ae-8417-44ba-b4e7-9e1ff188e51d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05954871","created_at":"2023-07-20T23:11:00.288Z","updated_at":"2024-07-02T16:35:00.306Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05954871","lead_sponsor":"Genentech, Inc.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR positive","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tagrisso (osimertinib) • migoprotafib (RLY-1971)"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 01/08/2024","start_date":" 01/08/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-29"},{"id":"8d11e7de-5fd7-49f6-b0e9-31e7346e7fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04800822","created_at":"2021-03-16T14:52:26.431Z","updated_at":"2024-07-02T16:35:06.982Z","phase":"Phase 1","brief_title":"PF-07284892 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04800822","lead_sponsor":"Pfizer","biomarkers":" ALK • ROS1 • NF1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive","tags":["ALK • ROS1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 06/18/2024","primary_completion_date":" 06/18/2024","study_txt":" Completion: 11/29/2025","study_completion_date":" 11/29/2025","last_update_posted":"2024-04-30"},{"id":"70578b33-80a9-42f4-9a13-82071422aadc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04528836","created_at":"2021-01-18T21:41:09.194Z","updated_at":"2024-07-02T16:35:13.988Z","phase":"Phase 1","brief_title":"First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04528836","lead_sponsor":"Navire Pharma Inc., a BridgeBio company","biomarkers":" EGFR • KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12","tags":["EGFR • KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BMS-986466"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 11/12/2020","start_date":" 11/12/2020","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-03-19"},{"id":"d64a4376-f3c6-468c-8bab-9e4a850eabdc","acronym":"Argonaut","url":"https://clinicaltrials.gov/study/NCT05480865","created_at":"2022-07-29T15:55:28.505Z","updated_at":"2024-07-02T16:35:21.318Z","phase":"Phase 1","brief_title":"SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation","source_id_and_acronym":"NCT05480865 - Argonaut","lead_sponsor":"Navire Pharma Inc., a BridgeBio company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • BMS-986466"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-02-01"},{"id":"ee17af4b-a504-4d7f-9a7e-75d62a8f9ff6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05621525","created_at":"2022-11-18T14:59:17.769Z","updated_at":"2024-07-02T16:35:26.381Z","phase":"Phase 1","brief_title":"Phase I Study of the BBP-398 in Patients With Advance Solid Tumors","source_id_and_acronym":"NCT05621525","lead_sponsor":"LianBio LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BMS-986466"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/18/2022","start_date":" 10/18/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-13"},{"id":"9c82a02e-5ff8-41e1-bc14-085d8f246f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05163028","created_at":"2021-12-20T16:53:57.143Z","updated_at":"2024-07-02T16:35:37.281Z","phase":"Phase 1","brief_title":"A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations","source_id_and_acronym":"NCT05163028","lead_sponsor":"HUYABIO International, LLC.","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR mutation","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HBI-2376"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-09-13"},{"id":"dde5d7d2-1dad-4eff-ab54-2b67e2cc553a","acronym":"HERKULES-2","url":"https://clinicaltrials.gov/study/NCT04959981","created_at":"2021-12-13T15:11:31.264Z","updated_at":"2024-07-02T16:35:42.103Z","phase":"Phase 1b","brief_title":"A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC","source_id_and_acronym":"NCT04959981 - HERKULES-2","lead_sponsor":"Erasca, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 09/02/2021","start_date":" 09/02/2021","primary_txt":" Primary completion: 04/27/2023","primary_completion_date":" 04/27/2023","study_txt":" Completion: 04/27/2023","study_completion_date":" 04/27/2023","last_update_posted":"2023-07-25"},{"id":"453c1951-7d33-4eda-a006-4c7a51c5f391","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886374","created_at":"2023-06-02T14:06:09.787Z","updated_at":"2024-07-02T16:35:42.306Z","phase":"Phase 1","brief_title":"A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05886374","lead_sponsor":"Hutchmed","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HMPL-415"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2023-07-21"},{"id":"8411cc8f-a982-4f1c-a6ee-8d632174e0c9","acronym":"RMC-4630-02","url":"https://clinicaltrials.gov/study/NCT03989115","created_at":"2021-01-18T19:36:51.447Z","updated_at":"2024-07-02T16:35:44.769Z","phase":"Phase 1/2","brief_title":"Dose-Esc/Exp RMC4630 \u0026 Cobi in Relapsed/Refractory Solid Tumors \u0026 RMC4630\u0026 Osi in EGFR+ Locally Adv/Meta NSCLC","source_id_and_acronym":"NCT03989115 - RMC-4630-02","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" EGFR • KRAS • BRAF • NF1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NF1 mutation • BRAF amplification","tags":["EGFR • KRAS • BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NF1 mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Cotellic (cobimetinib) • vociprotafib (RMC-4630)"],"overall_status":"Completed","enrollment":" Enrollment 113","initiation":"Initiation: 07/02/2019","start_date":" 07/02/2019","primary_txt":" Primary completion: 02/08/2022","primary_completion_date":" 02/08/2022","study_txt":" Completion: 02/08/2022","study_completion_date":" 02/08/2022","last_update_posted":"2023-06-26"},{"id":"0bc05807-8ef3-40d0-9ed4-10f0538739b7","acronym":"RMC-4630-03","url":"https://clinicaltrials.gov/study/NCT05054725","created_at":"2021-09-23T17:53:06.583Z","updated_at":"2024-07-02T16:35:51.630Z","phase":"Phase 2","brief_title":"Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies","source_id_and_acronym":"NCT05054725 - RMC-4630-03","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • vociprotafib (RMC-4630)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 12/30/2021","start_date":" 12/30/2021","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 03/03/2024","study_completion_date":" 03/03/2024","last_update_posted":"2023-04-03"},{"id":"0b6d3060-8f22-49b8-8ccf-8539c20c6118","acronym":"","url":"https://clinicaltrials.gov/study/NCT05715398","created_at":"2023-02-08T18:00:07.082Z","updated_at":"2024-07-02T16:35:55.802Z","phase":"Phase 1/2","brief_title":"BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05715398","lead_sponsor":"Shanghai Gopherwood Biotech Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • BR790"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-02-10"},{"id":"a6bd584d-e831-4a8e-b3a3-6c9a3a80fc5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03634982","created_at":"2021-01-18T17:51:01.596Z","updated_at":"2024-07-02T16:36:04.616Z","phase":"Phase 1","brief_title":"Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors","source_id_and_acronym":"NCT03634982","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS • BRAF • NF1","pipe":" | ","alterations":" KRAS G12C • BRAF mutation • KRAS G12 • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • BRAF mutation • KRAS G12 • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vociprotafib (RMC-4630)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2022-09-01"},{"id":"dec0e27d-576f-4620-b2f7-4fb083164458","acronym":"JAB-21822-1006","url":"https://clinicaltrials.gov/study/NCT05288205","created_at":"2022-03-21T20:54:45.507Z","updated_at":"2025-02-25T16:17:27.931Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","source_id_and_acronym":"NCT05288205 - JAB-21822-1006","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Airuikai (glecirasib) • sitneprotafib (JAB-3312)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2022-06-30"},{"id":"2482352c-3f42-43f1-a0f9-da11b351d807","acronym":"","url":"https://clinicaltrials.gov/study/NCT05369312","created_at":"2022-05-11T16:55:51.065Z","updated_at":"2024-07-02T16:36:08.596Z","phase":"Phase 1","brief_title":"Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients","source_id_and_acronym":"NCT05369312","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" KRAS • BRAF • NF1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NF1 mutation • KRAS G12","tags":["KRAS • BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NF1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BPI-442096"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2022-06-20"},{"id":"330ac409-c653-4ffe-b5ad-e37d750b01db","acronym":"HERKULES-4","url":"https://clinicaltrials.gov/study/NCT05279859","created_at":"2022-03-15T18:52:50.830Z","updated_at":"2024-07-02T16:36:08.894Z","phase":"Phase 1b/2","brief_title":"A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies","source_id_and_acronym":"NCT05279859 - HERKULES-4","lead_sponsor":"Erasca, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • ERAS-007 • ERAS-601"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-06-15"},{"id":"0b0004ce-6bfe-4d8e-982a-5d46b487e30e","acronym":"SHERPA","url":"https://clinicaltrials.gov/study/NCT04916236","created_at":"2021-06-07T15:53:34.728Z","updated_at":"2024-07-02T16:36:09.403Z","phase":"Phase 1","brief_title":"Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers","source_id_and_acronym":"NCT04916236 - SHERPA","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" EGFR • KRAS • PIK3CA • MET • PTEN • HRAS","pipe":"","alterations":" ","tags":["EGFR • KRAS • PIK3CA • MET • PTEN • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vociprotafib (RMC-4630) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-06-03"},{"id":"044ad04e-9242-4d5c-b71d-62ab6ac33aad","acronym":"STEM","url":"https://clinicaltrials.gov/study/NCT02970682","created_at":"2021-01-18T14:36:07.066Z","updated_at":"2024-07-02T16:36:58.181Z","phase":"Phase 2","brief_title":"SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer","source_id_and_acronym":"NCT02970682 - STEM","lead_sponsor":"Evgen Pharma","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • Sulforadex (sulforafan alfadex)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-07-12"}]